Gema Ariceta1, Laure Collard2, Saoussen Abroug3, Shabbir H Moochhala4, Edward Gould5, Abir Boussetta6, Mohamed Ben Hmida7, Sudarsana De8, Tracy E Hunley5, Faical Jarraya7, Gloria Fraga9,10, Ana Banos11, Elisabeth Lindner11, Bastian Dehmel11, Gesa Schalk12. 1. Hospital Vall d'Hebron, Barcelona, Spain. gariceta@vhebron.net. 2. Centre Hospitalier Umniversitaire de Liege, Liege, Belgium. 3. Hôpital Universitaire Sahloul, Sousse, Tunisia. 4. Royal Free Hospital, London, UK. 5. Vanderbilt University Hospital, Nashville, USA. 6. Charles Nicolle University Hospital, Tunis, Tunisia. 7. Hedi Chaker University Hospital, Sfax, Tunisia. 8. Nottingham Children's Hospital, Nottingham, UK. 9. Hospital Vall d'Hebron, Barcelona, Spain. 10. Hospital Sant Pau, Barcelona, Spain. 11. OxThera Intellectual Property AB, Stockholm, Sweden. 12. Kindernierenzentrum, Bonn, Germany.
Abstract
BACKGROUND: Primary hyperoxalurias (PHs) are rare genetic diseases that increase the endogenous level of oxalate, a waste metabolite excreted predominantly by the kidneys and also the gut. Treatments aim to improve oxalate excretion, or reduce oxalate generation, to prevent kidney function deterioration. Oxalobacter formigenes is an oxalate metabolizing bacterium. This Phase III, double-blind, placebo-controlled randomized trial investigated the effectiveness of orally administered Oxabact™, a lyophilized O. formigenes formulation, at reducing plasma oxalate levels in patients suffering from PH. METHODS: Subjects (≥ 2 years of age) with a diagnosis of PH and maintained but suboptimal kidney function (mean estimated glomerular filtration rate at baseline < 90 mL/min/1.73 m2) were eligible to participate. Subjects were randomized to receive Oxabact or placebo twice daily for 52 weeks. Change from baseline in plasma oxalate concentration at Week 52 was the primary study endpoint. RESULTS: Forty-three subjects were screened, 25 were recruited and one was discontinued. At Week 52, O. formigenes was established in the gut of subjects receiving Oxabact. Despite decreasing plasma oxalate level in subjects treated with Oxabact, and stable/increased levels with placebo, there was no significant difference between groups in the primary outcome (Least Squares mean estimate of treatment difference was - 3.80 μmol/L; 95% CI: - 7.83, 0.23; p-value = 0.064). Kidney function remained stable in both treatments. CONCLUSIONS: Oxabact treatment may have stabilized/reduced plasma oxalate versus a rise with placebo, but the difference over 12 months was not statistically significant (p = 0.06). A subtle effect observed with Oxabact suggests that O. formigenes may aid in preventing kidney stones. A higher resolution version of the Graphical abstract is available as Supplementary information.
BACKGROUND: Primary hyperoxalurias (PHs) are rare genetic diseases that increase the endogenous level of oxalate, a waste metabolite excreted predominantly by the kidneys and also the gut. Treatments aim to improve oxalate excretion, or reduce oxalate generation, to prevent kidney function deterioration. Oxalobacter formigenes is an oxalate metabolizing bacterium. This Phase III, double-blind, placebo-controlled randomized trial investigated the effectiveness of orally administered Oxabact™, a lyophilized O. formigenes formulation, at reducing plasma oxalate levels in patients suffering from PH. METHODS: Subjects (≥ 2 years of age) with a diagnosis of PH and maintained but suboptimal kidney function (mean estimated glomerular filtration rate at baseline < 90 mL/min/1.73 m2) were eligible to participate. Subjects were randomized to receive Oxabact or placebo twice daily for 52 weeks. Change from baseline in plasma oxalate concentration at Week 52 was the primary study endpoint. RESULTS: Forty-three subjects were screened, 25 were recruited and one was discontinued. At Week 52, O. formigenes was established in the gut of subjects receiving Oxabact. Despite decreasing plasma oxalate level in subjects treated with Oxabact, and stable/increased levels with placebo, there was no significant difference between groups in the primary outcome (Least Squares mean estimate of treatment difference was - 3.80 μmol/L; 95% CI: - 7.83, 0.23; p-value = 0.064). Kidney function remained stable in both treatments. CONCLUSIONS: Oxabact treatment may have stabilized/reduced plasma oxalate versus a rise with placebo, but the difference over 12 months was not statistically significant (p = 0.06). A subtle effect observed with Oxabact suggests that O. formigenes may aid in preventing kidney stones. A higher resolution version of the Graphical abstract is available as Supplementary information.
Authors: Farouk Mookadam; Travis Smith; Panupong Jiamsripong; Sherif E Moustafa; Carla G Monico; John C Lieske; Dawn S Milliner Journal: Circ J Date: 2010-09-29 Impact factor: 2.993
Authors: Shrikant R Mulay; Onkar P Kulkarni; Khader V Rupanagudi; Adriana Migliorini; Murthy N Darisipudi; Akosua Vilaysane; Daniel Muruve; Yan Shi; Fay Munro; Helen Liapis; Hans-Joachim Anders Journal: J Clin Invest Date: 2012-12-10 Impact factor: 14.808
Authors: Sander F Garrelfs; Yaacov Frishberg; Sally A Hulton; Michael J Koren; William D O'Riordan; Pierre Cochat; Georges Deschênes; Hadas Shasha-Lavsky; Jeffrey M Saland; William G Van't Hoff; Daniel G Fuster; Daniella Magen; Shabbir H Moochhala; Gesa Schalk; Eva Simkova; Jaap W Groothoff; David J Sas; Kristin A Meliambro; Jiandong Lu; Marianne T Sweetser; Pushkal P Garg; Akshay K Vaishnaw; John M Gansner; Tracy L McGregor; John C Lieske Journal: N Engl J Med Date: 2021-04-01 Impact factor: 91.245
Authors: Dawn S Milliner; Pierre Cochat; Sally-Anne Hulton; Jerome Harambat; Ana Banos; Bastian Dehmel; Elisabeth Lindner Journal: Pediatr Nephrol Date: 2021-01-30 Impact factor: 3.714
Authors: Felix Knauf; John R Asplin; Ignacio Granja; Insa M Schmidt; Gilbert W Moeckel; Rachel J David; Richard A Flavell; Peter S Aronson Journal: Kidney Int Date: 2013-06-05 Impact factor: 10.612